Extracellular Domain Mutation of ErbB2 Status in Japanese Lung Cancer Patients

Journal Title: Journal of Oncobiomarkers - Year 2013, Vol 1, Issue 2

Abstract

Purpose: The erbB pathway involves a family of tyrosine kinases and has contributed to resistance or sensitivity for chemotherapy in many tumor types. Somatic mutations of the erbB family receptor gene at kinase domain were found in lung cancer patients. However, the incidence of extracellular domain mutation of erbB2 in Japanese patients has been rarely described. We report on the incidence of these mutations and clinical factors associated with these mutations. Material and Methods: We have investigated extracellular domain mutations of erbB2 status in non-small cell lung cancer (NSCLC) patients by reverse transcript polymerase chain reaction (RT-PCR) and direct sequencing. The study included 210 surgically removed EGFR or ALK gene wild type lung cancer cases from Nagoya City University Hospital. Results: One G309E erbB2 mutation case was found from squamous cell carcinoma. Within adenocarcinoma, no erbB2 mutation was found in extracellular domain. We have previously detected six erbB2 mutations at kinase domain all in adenocarcinomas. Among the 7 erbB2 gene mutation cases, one case with kinase domain mutation was Hercep test positive. Conclusion: The extracellular domain mutation of erbB2 was rare in Japanese population. Although this mutation is rare, its identification could result in more precise treatment of patients. Keywords: Extracellular domain; squamous cell carcinoma; Lung cancer; Mutations; erbB2; G309E

Authors and Affiliations

Hidefumi Sasaki

Keywords

Related Articles

11β-Hydroxysteroid Dehydrogenase Type II is a Potential Target for Prevention of Colorectal Tumorigenesis

Colorectal cancer (CRC) is a leading cause of cancer death, yet primary prevention remains the best approach to reducing overall morbidity and mortality. There is a clear molecular link between cyclooxygenase-2 (COX-2)-d...

The Relative Fewness of Renal Metastases in Lung Cancer is Probably Explicable with the “Erythrocyte Associated Necrosis Factor” which may be an Oncobiomarker

There is profundity of lung cancer cells thrown into the circulation with each heart beat and the quantity of the quarter of the cardiac stroke volume being delivered to the kidneys. Despite both of these attractive attr...

IRF4 as an Oncogenic Biomarker for Hematological Malignancies

The lymphocyte-specific transcription factor Interferon (IFN) Regulatory Factor 4 (IRF4) is crucial for lymphocyte development. Importantly, IRF4 has potent oncogenic and transforming properties, and its intimate interac...

Suppression of Matrix Metalloproteinases -2 and -9 in Various Human Cancer Cell Lines by a Nutrient Mixture

The matrix metalloproteinases (MMPs) are a family of zinc containing endopeptidases that degrade various components of the extra cellular matrix. Among the many types of MMPs that have been identified, MMP-2 (gelatinase...

Low Cell Density Induced Epithelial-Mesenchymal Transition in MCF10A Cell is Regulated by Proteasome Activity

Epithelial-mesenchymal transition (EMT) is a key process in tumor progression and metastasis. Previous studies have shown that MCF10A human mammary epithelial cells undergo EMT when cultured at low cell density, but...

Download PDF file
  • EP ID EP206249
  • DOI 10.13188/2325-2340.1000006
  • Views 99
  • Downloads 0

How To Cite

Hidefumi Sasaki (2013). Extracellular Domain Mutation of ErbB2 Status in Japanese Lung Cancer Patients. Journal of Oncobiomarkers, 1(2), 1-5. https://europub.co.uk/articles/-A-206249